107 related articles for article (PubMed ID: 30016269)
1. Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients.
Song T; Mao F; Shi L; Xu X; Wu Z; Zhou J; Xiao M
Clin Chem Lab Med; 2018 Dec; 57(2):268-275. PubMed ID: 30016269
[TBL] [Abstract][Full Text] [Related]
2. Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer.
Chen W; Liao Y; Yang C; Fang Z; Liu B; Zheng X; Zhou C
Biomarkers; 2019 Sep; 24(6):524-529. PubMed ID: 31220949
[No Abstract] [Full Text] [Related]
3. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.
Vidal J; Muinelo L; Dalmases A; Jones F; Edelstein D; Iglesias M; Orrillo M; Abalo A; Rodríguez C; Brozos E; Vidal Y; Candamio S; Vázquez F; Ruiz J; Guix M; Visa L; Sikri V; Albanell J; Bellosillo B; López R; Montagut C
Ann Oncol; 2017 Jun; 28(6):1325-1332. PubMed ID: 28419195
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
Yu H; Han L; Yuan J; Sun Y
Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
[TBL] [Abstract][Full Text] [Related]
6. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
7. Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.
Li F; Huang J; Ji D; Meng Q; Wang C; Chen S; Wang X; Zhu Z; Jiang C; Shi Y; Liu S; Li C
Clin Transl Oncol; 2017 Oct; 19(10):1283-1291. PubMed ID: 28497422
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
9. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing.
Schmiegel W; Scott RJ; Dooley S; Lewis W; Meldrum CJ; Pockney P; Draganic B; Smith S; Hewitt C; Philimore H; Lucas A; Shi E; Namdarian K; Chan T; Acosta D; Ping-Chang S; Tannapfel A; Reinacher-Schick A; Uhl W; Teschendorf C; Wolters H; Stern J; Viebahn R; Friess H; Janssen KP; Nitsche U; Slotta-Huspenina J; Pohl M; Vangala D; Baraniskin A; Dockhorn-Dworniczak B; Hegewisch-Becker S; Ronga P; Edelstein DL; Jones FS; Hahn S; Fox SB
Mol Oncol; 2017 Feb; 11(2):208-219. PubMed ID: 28106345
[TBL] [Abstract][Full Text] [Related]
10. KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients.
Olmedillas López S; García-Olmo DC; García-Arranz M; Guadalajara H; Pastor C; García-Olmo D
Int J Mol Sci; 2016 Apr; 17(4):484. PubMed ID: 27043547
[TBL] [Abstract][Full Text] [Related]
11. Variations in transrenal DNA and comparison with plasma DNA as a diagnostic marker for colorectal cancer.
Tian F; Liao Y; Zhang Y
Int J Biol Markers; 2017 Oct; 32(4):e434-e440. PubMed ID: 28708207
[TBL] [Abstract][Full Text] [Related]
12. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
13. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.
Chen S; Zhao J; Cui L; Liu Y
Clin Transl Oncol; 2017 Mar; 19(3):332-340. PubMed ID: 27468867
[TBL] [Abstract][Full Text] [Related]
14. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
15. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
[TBL] [Abstract][Full Text] [Related]
16. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
17. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
[TBL] [Abstract][Full Text] [Related]
18. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.
Herbst A; Vdovin N; Gacesa S; Ofner A; Philipp A; Nagel D; Holdt LM; Op den Winkel M; Heinemann V; Stieber P; Graeven U; Reinacher-Schick A; Arnold D; Ricard I; Mansmann U; Hegewisch-Becker S; Kolligs FT
Int J Cancer; 2017 May; 140(9):2134-2144. PubMed ID: 28124380
[TBL] [Abstract][Full Text] [Related]
19. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
20. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
